The Vanguard Group, Inc. recently announced the acquisition of new stake in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). The institutional investor has increased its shareholding in the Healthcare company by 0.04% to 5.28 million shares with purchase of 1990.0 shares. This fresh investment now brings its stake to 5.91% valued currently at $1.13 million. In addition, Gratus Capital LLC raised its holdings by 74350.0 to 1.32 million shares.
With over 2.82 million Infinity Pharmaceuticals Inc. (INFI) shares trading Friday and a closing price of $0.20 on the day, the dollar volume was approximately $0.56 million. The shares have shown a negative half year performance of -87.08% and its price on 03/10/23 lost nearly -5.38%. Currently, there are 89.39M common shares owned by the public and among those 88.23M shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for INFI have a consensus price objective of $2.15. The analysts have set the share’s price value over the next 12 months at a high of $4.00 and a low of $0.30. The average price target is 95.49% above its recent price level and an upside to the estimated low will see the stock gain 33.33% over that period. But an upside of 95.0% will see the stock hit the forecast high price target while median target price for the stock is $2.15.
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 142,291 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Infinity Pharmaceuticals Inc. are Vanguard Total Stock Market Index, Polar Capital Funds Plc – Biotech, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 2.56 million shares of the company’s stock, all valued at over $0.55 million. Polar Capital Funds Plc – Biotech sold -2.17 million shares to see its total holdings shrink to 2.07 million shares valued at over $0.44 million and representing 2.32% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 1.41% of the shares outstanding.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ: INFI) opened at $0.203, down -$0.01 from a prior closing price of $0.21. However, the script later moved the day high at 0.2030, down -5.38%. The company’s stock has a 5-day price change of -17.37% and -58.95% over the past three months. INFI shares are trading -64.85% year to date (YTD), with the 12-month market performance down to -81.42% lower. It has a 12-month low price of $0.20 and touched a high of $1.76 over the same period. INFI has an average intraday trading volume of 956.00K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -49.60%, -63.33%, and -76.50% respectively.
Institutional ownership of Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares accounts for 35.70% of the company’s 89.39M shares outstanding. Mutual fund holders own 19.14%, while other institutional holders and individual stakeholders account for 22.53% and 11.12% respectively.
It has a market capitalization of $18.41M and a beta (3y monthly) value of 1.39. The earnings-per-share (ttm) stands at -$0.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.16% over the week and 12.65% over the month.
Analysts forecast that Infinity Pharmaceuticals Inc. (INFI) will achieve an EPS of -$0.03 for the current quarter, -$0.11 for the next quarter and -$0.43 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.12 while analysts give the company a high EPS estimate of $0.12. Comparatively, EPS for the current quarter was -$0.13 a year ago. Earnings per share for the fiscal year are expected to increase by 21.80%, and 0.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Infinity Pharmaceuticals Inc. (INFI) as a “Moderate Buy” at a consensus score of 2.70. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 2 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the INFI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on October 18, 2021, with the firm’s price target at $9. JP Morgan coverage for the Infinity Pharmaceuticals Inc. (INFI) stock in a research note released on August 02, 2021 offered a Overweight rating with a price target of $6. Wells Fargo was of a view on July 28, 2021 that the stock is Overweight, while B. Riley Securities gave the stock Buy rating on July 07, 2021, issuing a price target of $7. Truist on their part issued Buy rating on March 18, 2021.
